Skip to main content
×
×
Home

Mechanism of action of cariprazine

  • Stephen M. Stahl
Abstract

Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Mechanism of action of cariprazine
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Mechanism of action of cariprazine
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Mechanism of action of cariprazine
      Available formats
      ×
Copyright
References
Hide All
1.Stahl, SM. Stahl’s Essential Psychopharmacology., 4th ed. Cambridge, UK: Cambridge University Press; 2013.
2.Stahl, SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. In press.
3.Sautel, F, Griffon, N, Levesque, D, Pilon, C, Schwartz, J-C, Sokoloff, P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995; 6(2): 329332.
4.Freedman, SB, Patel, S, Marwood, R, et al. Expression and pharmacological characterization of the human D3 receptor. J Pharmacol Exp Ther. 1994; 268(1): 417426.
5.Kiss, B, Horváth, A, Némethy, Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328340.
6.Gyertyán, I, Kiss, B, Sághy, K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011; 59(6): 925935.
7.Zimnisky, R, Chang, G, Gyertyán, I, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013; 226(1): 91100.
8.Duman, RS, Duric, V, Banasr, M, et al. Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology. 2012; 38(Suppl 1): S84.
9.Stahl, SM. Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal side effects. CNS Spectr. 2013; 18(6): 285288.
10.Stahl, SM. Stahl’s Essential Psychopharmacology: The Prescribers Guide, 5th ed. New York: Cambridge University Press; 2014.
11.Citrome, L. The ABC’s of dopamine receptor partial agonists: aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015; 69(11): 12111220.
12.Kane, JM, Zukin, S, Wang, Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results From an international, phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367373.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed